DIHYDROERGOCORNINE MESYLATE, DIHYDROERGOCRISTINE MESYLATE, DIHYDRO-.ALPHA.-ERGOCRYPTINE MESYLATE, AND DIHYDRO-.BETA.-ERGOCRYPTINE MESYLATE (Ergoloid Mesylates) Nursing Considerations

What is the generic name?

DIHYDROERGOCORNINE MESYLATE, DIHYDROERGOCRISTINE MESYLATE, DIHYDRO-.ALPHA.-ERGOCRYPTINE MESYLATE, AND DIHYDRO-.BETA.-ERGOCRYPTINE MESYLATE

What is the Trade Name for DIHYDROERGOCORNINE MESYLATE, DIHYDROERGOCRISTINE MESYLATE, DIHYDRO-.ALPHA.-ERGOCRYPTINE MESYLATE, AND DIHYDRO-.BETA.-ERGOCRYPTINE MESYLATE?

Ergoloid Mesylates

What are the Indications for DIHYDROERGOCORNINE MESYLATE, DIHYDROERGOCRISTINE MESYLATE, DIHYDRO-.ALPHA.-ERGOCRYPTINE MESYLATE, AND DIHYDRO-.BETA.-ERGOCRYPTINE MESYLATE?

• INDICATIONS A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer’s dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient’s signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.

References: https://open.fda.gov/